Back
Alexander & Baldwin 10K Form
Sell
45
ALEX
Alexander & Baldwin
Last Price:
19.30
Seasonality Move:
1.09%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-01 | 10Q | ALEX/Alexander & Baldwin Quarterly |
2023-10-31 | 10Q | ALEX/Alexander & Baldwin Quarterly |
2023-08-02 | 10Q | ALEX/Alexander & Baldwin Quarterly |
2023-05-05 | 10Q | ALEX/Alexander & Baldwin Quarterly |
2022-11-03 | 10Q | ALEX/Alexander & Baldwin Quarterly |
2022-08-02 | 10Q | ALEX/Alexander & Baldwin Quarterly |
Receive ALEX News And Ratings
See the #1 stock for the next 7 days that we like better than ALEX
ALEX Financial Statistics
Sales & Book Value
Annual Sales: | $208.9M |
---|---|
Cash Flow: | $1.62M |
Price / Cash Flow: | 24.74 |
Annual Sales: | $13.74 |
Price / Book: | 1.41 |
Profitability
EPS (TTM): | 0.62000 |
---|---|
Net Income (TTM): | $44.58M |
Gross Margin: | $102.3M |
Return on Equity: | 4.42% |
Return on Assets: | 2.67% |
Alexander & Baldwin Earnings Forecast
Key Alexander & Baldwin Financial Ratios
- The Gross Profit Margin over the past 15 years for ALEX is 48.97%.
- The Selling, General & Administrative Expenses for ALEX have been equal to 16.52% of Gross Profit Margin.
- The Interest Expense is 77.18% of Operating Income.
- The Net Earning history of ALEX is 14.27% of Total Revenues.
- Per Share Earnings over the last 15 years have been positive in 7 years.
Alexander & Baldwin Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Diversified REITs |
Sector: | Real Estate |
Current Symbol: | ALEX |
CUSIP: | 014491 |
Website: | alexanderbaldwin.com |
Debt
Debt-to-Equity Ratio: | 0.47 |
---|---|
Current Ratio: | 0.28 |
Quick Ratio: | 0.2 |
Price-to-Earnings
Trailing P/E Ratio: | 47.12 |
---|---|
Forward P/E Ratio: | 0 |
ALEX Technical Analysis vs Fundamental Analysis
Sell
45
Alexander & Baldwin (ALEX)
is a Sell
Is Alexander & Baldwin a Buy or a Sell?
-
Alexander & Baldwin stock is rated a Sell
The current Alexander & Baldwin [ALEX] share price is $19.32. The Score for ALEX is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.